Bearing Point Capital LLC Sells 13,359 Shares of Veeva Systems Inc. $VEEV

Bearing Point Capital LLC reduced its stake in Veeva Systems Inc. (NYSE:VEEV) by 45.2% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 16,228 shares of the technology company’s stock after selling 13,359 shares during the period. Bearing Point Capital LLC’s holdings in Veeva Systems were worth $3,623,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Wormser Freres Gestion raised its stake in Veeva Systems by 48.8% in the fourth quarter. Wormser Freres Gestion now owns 186 shares of the technology company’s stock worth $42,000 after buying an additional 61 shares in the last quarter. BNP Paribas Financial Markets raised its stake in Veeva Systems by 27.1% in the fourth quarter. BNP Paribas Financial Markets now owns 298,806 shares of the technology company’s stock worth $66,702,000 after buying an additional 63,687 shares in the last quarter. Norges Bank bought a new position in Veeva Systems in the fourth quarter worth about $332,412,000. Alfreton Capital LLP bought a new position in Veeva Systems in the fourth quarter worth about $22,323,000. Finally, Eurizon Capital SGR S.p.A. bought a new position in Veeva Systems in the fourth quarter worth about $7,816,000. 88.20% of the stock is owned by institutional investors.

Trending Headlines about Veeva Systems

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: Veeva announced that Kindeva, a global CDMO, is adopting Veeva Quality Cloud to unify sites on a single platform, which supports Veeva’s growth narrative and could boost future recurring software revenue. Why Veeva Systems (VEEV) Stock Is Up Today
• Positive Sentiment: Coverage highlighting Veeva versus IQVIA points to strong industry tailwinds from life sciences digitization, with Veeva viewed as benefiting from AI adoption and a premium business model. Veeva vs. IQVIA: Which Life Sciences Tech Stock Holds More Promise?
• Neutral Sentiment: Several articles previewed Wall Street’s key metric estimates for Veeva’s upcoming quarter, suggesting investors are watching whether the company can meet growth expectations, but these pieces did not include a new earnings surprise or guidance update. Unveiling Veeva (VEEV) Q1 Outlook: Wall Street Estimates for Key Metrics
• Neutral Sentiment: Veeva was also highlighted as a trending stock and covered in analyst-style writeups noting a “Moderate Buy” consensus, which supports attention on the name but does not by itself change fundamentals. Veeva Systems Inc. (NYSE:VEEV) Given Average Recommendation of “Moderate Buy” by Analysts

Insider Activity at Veeva Systems

In other news, Director Priscilla Hung sold 750 shares of the stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $155.64, for a total transaction of $116,730.00. Following the sale, the director owned 3,253 shares in the company, valued at $506,296.92. This represents a 18.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.60% of the stock is currently owned by insiders.

Veeva Systems Stock Performance

Shares of NYSE VEEV opened at $173.97 on Friday. Veeva Systems Inc. has a fifty-two week low of $148.05 and a fifty-two week high of $310.50. The company has a 50 day simple moving average of $166.38 and a two-hundred day simple moving average of $199.77. The company has a market capitalization of $28.42 billion, a price-to-earnings ratio of 32.16, a P/E/G ratio of 0.77 and a beta of 0.92.

Veeva Systems (NYSE:VEEV) last announced its earnings results on Wednesday, March 4th. The technology company reported $2.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.94 by $0.12. Veeva Systems had a net margin of 28.44% and a return on equity of 13.80%. The business had revenue of $835.95 million during the quarter, compared to the consensus estimate of $810.95 million. During the same quarter last year, the firm earned $1.74 earnings per share. The business’s revenue for the quarter was up 16.0% on a year-over-year basis. Veeva Systems has set its FY 2027 guidance at 8.850- EPS and its Q1 2027 guidance at 2.130-2.14 EPS. On average, analysts forecast that Veeva Systems Inc. will post 6.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on VEEV shares. Piper Sandler decreased their price target on shares of Veeva Systems from $355.00 to $285.00 and set an “overweight” rating for the company in a research note on Thursday, March 5th. Wall Street Zen downgraded shares of Veeva Systems from a “buy” rating to a “hold” rating in a research note on Sunday, March 22nd. Barclays decreased their target price on shares of Veeva Systems from $305.00 to $250.00 and set an “overweight” rating for the company in a research note on Wednesday, February 25th. UBS Group raised their target price on shares of Veeva Systems from $200.00 to $220.00 and gave the company a “neutral” rating in a research note on Thursday, March 5th. Finally, Truist Financial reaffirmed a “buy” rating and set a $262.00 target price (down from $275.00) on shares of Veeva Systems in a research note on Thursday, March 5th. Sixteen analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Veeva Systems presently has an average rating of “Moderate Buy” and an average price target of $276.52.

About Veeva Systems

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.